Affordable Access

deepdyve-link
Publisher Website

[Detection of RAS genes mutation using the Cobas® method in a private laboratory of pathology: Medical and economical study in comparison to a public platform of molecular biology of cancer].

Authors
  • Albertini, Anne-Flore1
  • Raoux, Delphine2
  • Neumann, Frédéric2
  • Rossat, Stéphane2
  • Tabet, Farid2
  • Pedeutour, Florence3
  • Duranton-Tanneur, Valérie3
  • Kubiniek, Valérie3
  • Vire, Olivier2
  • Weinbreck, Nicolas2
  • 1 Laboratoire Médipath, pôle d'excellence Jean-Louis, 263, Via Nova, 83600 Fréjus, France. Electronic address: [email protected] , (France)
  • 2 Laboratoire Médipath, pôle d'excellence Jean-Louis, 263, Via Nova, 83600 Fréjus, France. , (France)
  • 3 CHU de Nice, faculté de médecine, laboratoire de génétique somatique des tumeurs solides, 22, avenue de Valombrose, 06107 Nice cedex 02, France. , (France)
Type
Published Article
Journal
Bulletin du Cancer
Publisher
Elsevier
Publication Date
Jan 01, 2017
Volume
104
Issue
7-8
Pages
662–674
Identifiers
DOI: 10.1016/j.bulcan.2017.05.005
PMID: 28688743
Source
Medline
Keywords
License
Unknown

Abstract

In France, determination of the mutation status of RAS genes for predictive response to anti-EGFR targeted treatments is carried out by public platforms of molecular biology of cancer created by the French National Cancer Institute. This study aims to demonstrate the feasibility of these analyses by a private pathology laboratory (MEDIPATH) as per the requirements of accreditation. We retrospectively studied the mutation status of KRAS and NRAS genes in 163 cases of colorectal metastatic cancer using the Cobas® technique. We compared our results to those prospectively obtained through pyrosequencing and allelic discrimination by the genetic laboratory of solid tumors at the Nice University Hospital (PACA-EST regional platform). The results of both series were identical: 98.7% positive correlation; negative correlation of 93.1%; overall correlation of 95.7% (Kappa=0.92). This study demonstrates the feasibility of molecular analysis in a private pathology laboratory. As this practice requires a high level of guarantee, its accreditation, according to the NF-EN-ISO15189 quality compliance French standard, is essential. Conducting molecular analysis in this context avoids the steps of routing the sample and the result between the pathology laboratory and the platform, which reduces the overall time of rendering the result. In conclusion, the transfer of some analysis from these platforms to private pathology laboratories would allow the platforms to be discharged from a part of routine testing and therefore concentrate their efforts to the development of new analyses constantly required to access personalized medicine.

Report this publication

Statistics

Seen <100 times